Abstract
The farnesoid X receptor (FXRα) is a metabolic nuclear receptor and bile acid sensor expressed in the liver and intestine. Physiological studies have shown that FXR.. exerts regulatory roles in bile acids, lipid and glucose homeostasis. FXR ligands of steroidal and non-steroidal structure have been described. Both ligand groups have shown limitations in preclinical studies regarding their absorption, metabolism, target interactions and intrinsic toxicity. Inhibition of bile acid synthesis and basolateral transporters in the liver as well as reduction of high density lipoprotein (HDL) in the plasma are the major unwanted effects seen with these ligands. Several FXRα modulators are currently being generated with the aim of targeting FXRα isoforms by exploiting the relative unselectivity of the ligand binding domain of the receptor. Structure- activity relationship studies have shown that FXRα could be activated by structurally different ligands and that receptor occupancy by these ligands generates different patterns of gene activation as a result of specific conformational changes of the receptor or differential dislodgement of co-repressor or recruitment of co-activators. Generation of modulators that selectively target specific FXRα responsive elements are an interesting strategy to overcome the limitations of currently available FXR ligands.
Current Medicinal Chemistry
Title: Targeting Farnesoid-X-Receptor: From Medicinal Chemistry to Disease Treatment
Volume: 17 Issue: 2
Author(s): S. Fiorucci, A. Mencarelli, E. Distrutti, G. Palladino and S. Cipriani
Affiliation:
Abstract: The farnesoid X receptor (FXRα) is a metabolic nuclear receptor and bile acid sensor expressed in the liver and intestine. Physiological studies have shown that FXR.. exerts regulatory roles in bile acids, lipid and glucose homeostasis. FXR ligands of steroidal and non-steroidal structure have been described. Both ligand groups have shown limitations in preclinical studies regarding their absorption, metabolism, target interactions and intrinsic toxicity. Inhibition of bile acid synthesis and basolateral transporters in the liver as well as reduction of high density lipoprotein (HDL) in the plasma are the major unwanted effects seen with these ligands. Several FXRα modulators are currently being generated with the aim of targeting FXRα isoforms by exploiting the relative unselectivity of the ligand binding domain of the receptor. Structure- activity relationship studies have shown that FXRα could be activated by structurally different ligands and that receptor occupancy by these ligands generates different patterns of gene activation as a result of specific conformational changes of the receptor or differential dislodgement of co-repressor or recruitment of co-activators. Generation of modulators that selectively target specific FXRα responsive elements are an interesting strategy to overcome the limitations of currently available FXR ligands.
Export Options
About this article
Cite this article as:
Fiorucci S., Mencarelli A., Distrutti E., Palladino G. and Cipriani S., Targeting Farnesoid-X-Receptor: From Medicinal Chemistry to Disease Treatment, Current Medicinal Chemistry 2010; 17 (2) . https://dx.doi.org/10.2174/092986710790112666
DOI https://dx.doi.org/10.2174/092986710790112666 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Natural Polyphenols and Diabetes: Understanding their Mechanism of Action)
Current Medicinal Chemistry Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Danger-Detector NKG2D: Immunosurveillance of Induced Self and Modulation by Cytokines and Soluble Ligands
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Cellular and Molecular Mechanisms of Dementia: Decoding the Causal link of Diabetes Mellitus in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Assessment of Cardiac Performance with Magnetic Resonance Imaging
Current Cardiology Reviews Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz
Current HIV Research Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Diabetes Mellitus: Novel Insights, Analysis and Interpretation of Pathophysiology and Complications Management with Imidazole-Containing Peptidomimetic Antioxidants
Recent Patents on Drug Delivery & Formulation Study of Cord Blood Levels of Erythropoietin, Bilirubin and Reticulocyte Count as Early Predictors of Neonatal Hyperbilirubinemia
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Inflammatory Markers in Elderly Type 2 Diabetic Patients with Mild Cognitive Impairment
Current Diabetes Reviews Postprandial Lipaemia, Haemostasis, Inflammatory Response and other Emerging Risk Factors for Cardiovascular Disease: The Influence of Fatty Meals
Current Nutrition & Food Science Practical Recommendations for Familial Combined Hyperlipidemia Diagnosis and Management: An Update
Vascular Disease Prevention (Discontinued) Adherence to Treatment, Arterial Stiffness and Cognitive Function in Irbesartan- Treated Newly Diagnosed Hypertensive Patients
Current Vascular Pharmacology Type 2 Diabetes and Heart Failure: Challenges and Solutions
Current Cardiology Reviews Purification of Paraoxonase Enzyme From the Sera of Patients with Behcet’s Disease and Analyzing the Effects of the Drugs Containing Imuran (Azathioprine), Prednisolone (Methylprednisolone) and Colchium (Colchicine)
Drug Metabolism Letters Natural Compounds Used as Therapies Targeting to Amyotrophic Lateral Sclerosis
Current Pharmaceutical Biotechnology Network Insights into the Genes Regulated by Hepatocyte Nuclear Factor 4 in Response to Drug Induced Perturbations: A Review
Current Drug Discovery Technologies Low Testosterone and Diabetes
Current Diabetes Reviews Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets Human Platelet-Derived Growth Factor Enhances Healing of Ulcers Situated on Non-Foot Sites in Diabetics. A Pilot Study
Current Drug Therapy